Markets:

Overview

News

Currencies

International

Treasuries

Small Pharma Inc (OP:DMTTF)

N/A UNCHANGED

Last Price Updated: 3:59 PM EDT, Oct 20, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Small Pharma Inc

< Previous 1 2 3 4 5 6 7 8 Next >

Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25

January 24, 2023

From Small Pharma Inc.

Via GlobeNewswire

Comparing Psychedelics' Administration Routes: Are Intramuscular Injections More Effective Than Intravenous? ↗

January 11, 2023

Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) has dosed the first patient in its Phase 1 clinical trial assessing intramuscular (IM) versus intravenous (IV) administration of its...

Via Benzinga

First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026

January 09, 2023

Study will compare the profile of intramuscular versus intravenous SPL026 administration

From Small Pharma Inc.

Via GlobeNewswire

Psyched: Canada's Psychedelic Therapy Guidelines, $39M Series B For Next-Gen Drugs, Mexico's Ancestral Roots & More ↗

December 28, 2022

Canada: Fed Guidelines For Psychedelic Therapy, Quebec Treatment Costs, Access And Magic Mushrooms Dispensaries

Via Benzinga

This IV Psychedelic-Based Compound Completes Phase 2a Trial, Company Gets Extra IP Coverage ↗

December 22, 2022

Short-acting psychedelics biotech company Small Pharma Inc.

Via Benzinga

Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property

December 22, 2022

From Small Pharma Inc.

Via GlobeNewswire

Analyzing Psychedelics & Traditional Pharma Interaction: New Clinical Trial Begins Dosing ↗

December 19, 2022

Psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) confirmed that the first patient has been dosed in its Phase 1b study assessing the interaction between selective serotonin reuptake inhibitors...

Via Benzinga

How Certain Psychedelics Produce Brain And Behavior Changes: UCL Leads New Study ↗

December 16, 2022

The University College London (UCL) is conducting a new research project called “Understanding Neuroplasticity Induced by Tryptamines (UNITy)” aimed at assessing brain changes and neuroplasticity...

Via Benzinga

First Patient Dosed in Small Pharma’s Drug Interaction Study

December 15, 2022

Open-label study will assess the interaction between SSRI antidepressants and SPL026

From Small Pharma Inc.

Via GlobeNewswire

Small Pharma To Support University College London Research Project on Neuroplasticity

December 14, 2022

Small Pharma will provide SPL026 for the brain-imaging study, which seeks to explore how psychedelic-induced brain changes impact cognition, behaviour and well-being

From Small Pharma Inc.

Via GlobeNewswire

Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium

December 08, 2022

From Small Pharma Inc.

Via GlobeNewswire

Psychedelic Stock Gainers And Losers From November 24, 2022 ↗

November 24, 2022

Via Benzinga

Psychedelic Stock Gainers And Losers From November 23, 2022 ↗

November 23, 2022

Via Benzinga

Small Pharma to Participate in November Investor and Healthcare Conferences

November 11, 2022

From Small Pharma Inc.

Via GlobeNewswire

Psychedelic Stock Gainers And Losers From November 8, 2022 ↗

November 08, 2022

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 3.85% at $0.14

Via Benzinga

Compass Pathways, Allied Among Top Psychedelic Movers Of Today ↗

November 07, 2022

GAINERS: Allied (OTC:ALID) shares closed up 4.10% at $0.44

Via Benzinga

Psychedelic Stock Gainers And Losers From November 3, 2022 ↗

November 03, 2022

GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 4.80% at $10.27

Via Benzinga

Compass Pathways, Small Pharma Among Top Psychedelic Movers Of Today ↗

November 02, 2022

GAINERS: GH Research (NASDAQ:GHRS) shares closed up 3.90% at $10.39 LOSERS:

Via Benzinga

This Novel Short-Acting Psychedelic Compound Is Ready For First Phase 1 Clinical Try-Out ↗

October 31, 2022

Small Pharma Inc.

Via Benzinga

Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028

October 31, 2022

From Small Pharma Inc.

Via GlobeNewswire

Revive Therapeutics, Small Pharma Among Top Psychedelic Movers Of Today ↗

October 27, 2022

GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 3.00% at $0.87

Via Benzinga

Psychedelic Stock Gainers And Losers From October 26, 2022 ↗

October 26, 2022

GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 5.39% at $0.18

Via Benzinga

Psychedelic Stock Gainers And Losers From October 25, 2022 ↗

October 25, 2022

GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 6.24% at $10.39

Via Benzinga

Allied, Small Pharma Among Top Psychedelic Movers Of Today ↗

October 21, 2022

GAINERS: Allied (OTC:ALID) shares closed up 10.21% at $0.53

Via Benzinga

This Pharma Company Just Scored Another Psychedelics Patent And Set Its Sights On 70 More ↗

October 19, 2022

Short-acting psychedelics biotech firm Small Pharma Inc.

Via Benzinga

Second United States Patent Granted for Small Pharma’s Psychedelics Portfolio

October 19, 2022

From Small Pharma Inc.

Via GlobeNewswire

Psychedelic Stock Gainers And Losers From October 18, 2022 ↗

October 18, 2022

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 15.76% at $0.14

Via Benzinga

Small Pharma's Q2 2023 Financial Results, 'Ultra Short-Acting Psychedelic Program' Underway ↗

October 18, 2022

Small Pharma Inc. (OTCQB: DMTTF), a biotech company developing short-acting psychedelic-assisted therapies for diverse mental health disorders, reported its financial results for the three and six...

Via Benzinga

Small Pharma Reports Fiscal Second Quarter 2023 Highlights

October 14, 2022

From Small Pharma Inc.

Via GlobeNewswire

Small Pharma, Cybin Among Top Psychedelic Movers Of Today ↗

October 14, 2022

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 9.12% at $0.12

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Small Pharma Inc (OP:DMTTF)

All News about Small Pharma Inc

Starting at $3.75/week.

Subscribe Today